The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review

Koen Demyttenaere, Zeno Van Duppen, Koen Demyttenaere, Zeno Van Duppen

Abstract

Treatment-resistant depression refers to major depressive disorder, treatment of the disorder, and failure to obtain an "acceptable" outcome. Regarding the disorder, the heterogeneous concept of major depressive disorder and the multiple definitions of treatment-resistant depression, hesitating between a categorical and a more dimensional approach, as well as the divergence between diagnostic criteria and the items in the assessment scales are a source of confusion. Classifications do not take into account the dramatic influence of patient characteristics strongly impacting outcome, although these can be the cause of so-called pseudo-resistance. Outcome is the result of spontaneous evolution, nonspecific factors (including placebo), and active treatment factors. These should be differentiated to have a reliable estimation of the impact of different treatment modalities before we can asses treatment-resistant depression or before we can ascertain the (non)efficacy of treatments for treatment-resistant depression.The impact and burden of major depressive disorder and treatment-resistant depression are immense and go far beyond their economic cost. It is often forgotten that both are not only associated with increased suicidality but also with nonsuicidal mortality and that both can even result in requests for assisted dying. The caregiver burden and associated stigma are also too often overlooked despite that it has been suggested that they do influence (treatment) outcome.

References

    1. American Psychiatric Assocation (2013)Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Assocation.
    1. Banankhah SK, Friedmann E, Thomas S(2015)Effective treatment of depression improves post-myocardial infarction survival. World J Cardiol 7:215–223.
    1. Benedetti F.(2008)Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48:33–60.
    1. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK(2005)Neurobiological mechanisms of the placebo effect. J Neurosci 25:10390–10402.
    1. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN(2009)Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197–206.
    1. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A(2007)The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843–853.
    1. Bostwick JM, Pankratz VS(2000)Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925–1932.
    1. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann PG, Czajkowski SM, Jaffe AS, ENRICHD Investigators (2004)Depression and late mortality after myocardial infarction in the enhancing recovery in coronary heart disease (ENRICHD) study. Psychosom Med 66:466–474.
    1. Carney RM, Freedland KE(2009)Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 166:410–417.
    1. Carvalho AF, Machado JR, Cavalcante JL(2008)Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 22:7–12.
    1. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D(2011)Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the hypericum depression trial study group. J Clin Psychiatry 72:1669–1676.
    1. Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D(2015)Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the hypericum depression trial study group. Asian J Psychiatr 13:23–29.
    1. Conway CR, George MS, Sackeim HA(2017)Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry 74:9–10.
    1. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM(2002)The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63:963–971.
    1. de Jonge P, Honig A, van Melle JP, Schene AH, Kuyper AM, Tulner D, Schins A, Ormel J, MIND-IT Investigators (2007)Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 164:1371–1378.
    1. Demyttenaere K, Verhaeghen A, Dantchev N, Grassi L, Montejo AL, Perahia DG, Quail D, Reed C, Tylee A, Bauer M(2009)“Caseness” for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories. Prim Care Companion J Clin Psychiatry 11:307–315.
    1. Demyttenaere K, Reines EH, Lönn SL, Lader M(2011)Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis. Prim Care Companion CNS Disord 13:PCC.10m01080.
    1. Demyttenaere K, Donneau AF, Albert A, Ansseau M, Constant E, van Heeringen K(2015)What is important in being cured from: does discordance between physicians and patients matter?J Affect Disord 174:372–377.
    1. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ(2009)The maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry 70:952–957.
    1. Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ(2012)Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry 201:369–375.
    1. Fonagy P, Rost F, Carlyle JA, McPherson S, Thomas R, Pasco Fearon RM, Goldberg D, Taylor D(2015)Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the tavistock adult depression study (TADS). World Psychiatry 14:312–321.
    1. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM(1991)Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855.
    1. Fried EI, Nesse RM(2015)Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord 172:96–102.
    1. Gale CR, Batty GD, Osborn DP, Tynelius P, Whitley E, Rasmussen F(2012)Association of mental disorders in early adulthood and later psychiatric hospital admissions and mortality in a cohort study of more than 1 million men. Arch Gen Psychiatry 69:823–831.
    1. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, Burton WN, Tran QV, Pikalov A, Goetzel RZ(2010)Cost burden of treatment resistance in patients with depression. Am J Manag Care 16:370–377.
    1. Glassman AH, Bigger JT Jr, Gaffney M(2009)Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch Gen Psychiatry 66:1022–1029.
    1. Goldberg D.(2011)The heterogeneity of “major depression”. World Psychiatry 10:226–228.
    1. Gostin LO, Roberts AE(2016)Physician-assisted dying: a turning point?JAMA 315:249–250.
    1. Greenberg PE, Birnbaum HG(2005)The economic burden of depression in the US: societal and patient perspectives. Expert Opin Pharmacother 6:369–376.
    1. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC(2015)The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76:155–162.
    1. Hypericum Depression Trial Study Group (2002)Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 287:1807–1814.
    1. Kampermann L, Nestoriuc Y, Shedden-Mora MC(2017)Physicians’ beliefs about placebo and nocebo effects in antidepressants—an online survey among German practitioners. PLoS One 12:e0178719.
    1. Kim SY, De Vries RG, Peteet JR(2016)Euthanasia and assisted suicide of patients with psychiatric disorders in the Netherlands 2011 to 2014. JAMA Psychiatry 73:362–368.
    1. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N(2013)Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One 8:e76882.
    1. Kwan BM, Dimidjian S, Rizvi SL(2010)Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behav Res Ther 48:799–804.
    1. Lawrence D, Hancock KJ, Kisely S(2013)The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 346:f2539.
    1. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM(2008)The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156–165.
    1. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA(2002)The functional neuroanatomy of the placebo effect. Am J Psychiatry 159:728–737.
    1. Mueller TI, Keller MB, Leon AC, Solomon DA, Shea MT, Coryell W, Endicott J(1996)Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 53:794–799.
    1. Nelson JC, Papakostas GI(2009)Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991.
    1. Nemeroff CB.(2007)Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68:17–25.
    1. Nutt DJ.(2008)Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69:4–7.
    1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B, CDBE2010 study group European Brain Council (2012)The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162.
    1. Olin B, Jayewardene AK, Bunker M, Moreno F(2012)Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. PLoS One 7:e48002.
    1. Papakostas GI, Fava M(2009)Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34–40.
    1. Perlick DA, Miklowitz DJ, Link BG, Struening E, Kaczynski R, Gonzalez J, Manning LN, Wolff N, Rosenheck RA(2007)Perceived stigma and depression among caregivers of patients with bipolar disorder. Br J Psychiatry 190:535–536.
    1. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M(2005)Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 25:336–341.
    1. Pfeiffer PN, Kim HM, Ganoczy D, Zivin K, Valenstein M(2013)Treatment-resistant depression and risk of suicide. Suicide Life Threat Behav 43:356–365.
    1. Phelan JC, Bromet EJ, Link BG(1998)Psychiatric illness and family stigma. Schizophr Bull 24:115–126.
    1. Rane LJ, Fekadu A, Papadopoulos AS, Wooderson SC, Poon L, Markopoulou K, Cleare AJ(2012)Psychological and physiological effects of caring for patients with treatment-resistant depression. Psychol Med 42:1825–1833.
    1. Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, Mcintyre RS, Kennedy SH(2014)Treatment-resistant depression in primary care across Canada. Can J Psychiatry 59:349–357.
    1. Ruhé HG, van Rooijen G, Spijker J, Peeters FP, Schene AH(2012)Staging methods for treatment resistant depression. A systematic review. J Affect Disord 137:35–45.
    1. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C(1986)The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatry Res 18:65–87.
    1. Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, Bucholz KK, Owen R, Lustman PJ(2012)Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry 200:137–142.
    1. Schuklenk U, Van de Vathorst S (2015) Treatment-resistant major depressive disorder and assisted dying. J Med Ethics 41:577–583.
    1. Sinyor M, Schaffer A, Levitt A(2010)The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 55:126–135.
    1. Souery D, Papakostas GI, Trivedi MH(2006)Treatment-resistant depression. J Clin Psychiatry 67:16–22.
    1. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J, Group for the Study of Resistant Depression (2007)Clinical factors associated with treatment resistance in major depressive disorder: results from a european multicenter study. J Clin Psychiatry 68:1062–1070.
    1. Struening EL, Perlick DA, Link BG, Hellman F, Herman D, Sirey JA(2001)Stigma as a barrier to recovery: the extent to which caregivers believe most people devalue consumers and their families. Psychiatr Serv 52:1633–1638.
    1. Tabeleão V, Tomasi E, de Avila Quevedo L(2017)A randomized, controlled trial of the effectiveness of a psychoeducational intervention on family caregivers of patients with mental disorders. Community Ment Health J 54:211–217.
    1. Targum SD.(2014)Identification and treatment of antidepressant tachyphylaxis. Innov Clin Neurosci 11:24–28.
    1. Thienpont L, Verhofstadt M, Van Loon T, Distelmans W, Audenaert K, De Deyn PP(2015)Euthanasia requests, procedures and outcomes for 100 belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open 5:e007454.
    1. Vandenberghe J.(2018)Physician-assisted suicide and psychiatric illness. N Engl J Med 378:885–887.
    1. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, van den Brink RH, van den Berg MP(2004)Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66:814–822.
    1. van Wijngaarden B, Schene AH, Koeter MW(2004)Family caregiving in depression: impact on caregivers’ daily life, distress, and help seeking. J Affect Disord 81:211–222.
    1. Viola S, Moncrieff J(2016)Claims for sickness and disability benefits owing to mental disorders in the UK: trends from 1995 to 2014. Br J Psych Open 2:18–24.
    1. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR(2007)The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 9:449–459.
    1. Whiteford HA, Harris MG, McKeon G, Baxter A, Pennell C, Barendregt JJ, Wang J(2013)Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol Med 43:1569–1585.
    1. World Health Organization (2017)Depression and other common mental disorders: global health estimates. Geneva: World Health Organization.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel